Etoposide (VP-16-213, NSC 141540)

Potent anti-cancer compound. Induces apoptosis in normal and tumor cell lines.\n DNA Topoisomerase II activity inhibitor. Increases Topo II-mediated DNA breakage primarily by inhibiting the ability of the enzyme to religate cleaved nucleic acid molecules. Does not lead to immediate block of DNS synthesis, induces a progressive inhibition of DNA replication.p53 activator.\nBlocks the cell cycle between the end of the S phase and the early G2 phase.\n\nOncoprotein Mdm2 synthesis inhibitor.\n Apoptosis inducer through the cytochrome c/Apaf-1/caspase-9 pathway and the Fas-mediated death signaling pathway.\nCell cycle checkpoint activator. Affects gene expression at different levels (chromatin remodeling, transcription and alternative splicing).\nChemotherapeutic compound used in cancers.\n Used in conditioning regimen prior to a bone marrow or blood stem cell transplantation.\n\n\n\nStorage and Stability:\nShort-term Storage: +20 degrees C\nLong-term Storage: +20 degrees C\nStable for at least 2 years after receipt when stored at +20 degrees C. Store solutions in DMSO at 4 degrees C. After reconstitution, prepare aliquots and store at -20 degrees C.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

044777

Size

25mg

Purity

>98% (HPLC)

References

Product Reference: \n?The podophyllotoxin derivatives VP16-213 and VM26: B.F. Issell; Cancer Chemother. Pharmacol. 7, 73 (1982)\n?Topoisomerase-specific drug sensitivity in relation to cell cycle progression: K.C. Chow & W.E. Ross; Mol. Cell. Biol. 7, 3119 (1987)\n?Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents: R.B. Tishler, et al.; Cancer Res. 53, 2212 (1993)\n?Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes: D.A. Burden, et al.; J. Biol. Chem. 271, 29238 (1996)\n?Cell death induced by topoisomerase-targeted drugs: more questions than answers: S.H. Kaufmann; Biochim. Biophys. Acta 1400, 195 (1998) (Review)\n?Etoposide: four decades of development of a topoisomerase II inhibitor: K.R. Hande; Eur. J. Cancer 34, 1514 (1998) (Review)\n?Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop: E.L. Arriola, et al.; Oncogene 18, 1081 (1999)\n?Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: evidence of commitment to apoptosis rather than mitotic cell death: R.J. Sleiman & B.W. Stewart; Clin. Cancer Res. 6, 3756 (2000)\n?Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells: M. Sawada, et al.; Cell Death Differ. 7, 761 (2000)\n?Distinct pathways for stimulation of cytochrome c release by etoposide: J.D. Robertson, et al.; J. Biol. Chem. 275, 32438 (2000)\n?Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis: C.A. Johnson, et al.; J. Biol. Chem. 276, 4539 (2001)\n?Etoposide: discovery and medicinal chemistry: P. Meresse, et al.; Curr. Med. Chem. 11, 2443 (2004) (Review)\n?Etoposide, topoisomerase II and cancer: E.L. Baldwin & N. Osheroff; Curr. Med. Chem. Anticancer Agents 5, 363 (2005) (Review)\n?The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway: R. Rossi, et al.; Cancer Res. 66, 1675 (2006)\n?Cellular response to etoposide treatment: A. Montecucco & G. Biamonti; Cancer Lett. 252, 9 (2007) (Review)\n?Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy: W.A. Wood, et al.; Biol. Blood Marrow. Transplant. 17, 141 (2011)\n?

Alternative Names

VP-16-213, NSC 141540